Get started
Author

Piers Gaunt

Observed names: Gaunt, P., Gaunt, Piers, P Gaunt, P. Gaunt, Piers Graunt
ORCID: 0000-0001-8665-300X
Observed ORCID: 0000-0001-8665-300X
OpenAlex ID: A5074685337
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 · Matthew James Armstrong, Piers Gaunt, et al. · The Lancet · 2,241
Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation
2015 · Keith Wheatley, Jayne S. Wilson, et al. · Cancer Treatment Reviews · 82
Early phase clinical trials extension to guidelines for the content of statistical analysis plans
2022 · Victoria Homer, Christina Yap, et al. · BMJ · 57
PDF
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
2013 · Matthew J Armstrong, Darren Barton, et al. · BMJ Open · 52
PDF
The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma
2012 · Tomoki Nakamura, Robert Grimer, et al. · European Journal of Cancer · 51
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial
2022 · Penella Woll, Piers Gaunt, et al. · Lung Cancer · 42
PDF
Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial
2021 · A. Lorenc, M. Wells, et al. · Clinical Oncology · 38
PDF
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.
2016 · Paul D. Nathan, Piers Gaunt, et al. · Journal of Clinical Oncology · 29
The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma
2017 · Laura Forker, Piers Gaunt, et al. · British Journal of Cancer · 22
PDF
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
2024 · Hisham Mehanna, Piers Gaunt, et al. · Trials · 21
PDF
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial
2017 · David Ferry, Lucinda Billingham, et al. · European Journal of Cancer · 21
PDF
Feasibility of Dose-escalated Hypofractionated Chemoradiation in Human Papilloma Virus-negative or Smoking-associated Oropharyngeal Cancer
2018 · S. Meade, P. Gaunt, et al. · Clinical Oncology · 20
P1.07-015 STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC
2017 · Penella Woll, Piers Gaunt, et al. · Journal of Thoracic Oncology · 20
PDF
Vortex Trial: A Randomized Controlled Multicenter Phase 3 Trial of Volume of Postoperative Radiation Therapy Given to Adult Patients With Extremity Soft Tissue Sarcoma (STS)
2016 · M.H. Robinson, P. Gaunt, et al. · International Journal of Radiation Oncology*Biology*Physics · 17
PDF
Phase III randomised controlled trial (RCT) comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer (CompARE).
2017 · Hisham Mohamed Mehanna, Mehmet Sen, et al. · Journal of Clinical Oncology · 15
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
2023 · Penella J. Woll, Piers Gaunt, et al. · British Journal of Cancer · 14
PDF
G01 : Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, doubleblinded, randomised, placebo-controlled phase II trial
2015 · M.J. Armstrong, P. Gaunt, et al. · Journal of Hepatology · 13
PET-CT-guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head neck cancer patients (PETNECK2): study protocol for a multicentre feasibility study and non-inferiority, randomised, phase III trial
2024 · Paul Nankivell, Piers Gaunt, et al. · BMC Cancer · 10
PDF
Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma
2023 · Laura J. Forker, Becky Bibby, et al. · British Journal of Cancer · 6
PDF
1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)
2025 · H.M. Mehanna, P. Gaunt, et al. · Annals of Oncology · 5
Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy
2016 · Matthew J. Armstrong, Piers Gaunt, et al. · Hepatology · 5
S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients
2011 · L. J. Billingham, P. Gaunt, et al. · Thorax · 5
PDF
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma—EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial
2026 · Brennan Bernadette, Laura Kirton, et al. · British Journal of Cancer · 3
OC-016 Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase ii trial
2015 · MJ Armstrong, P Gaunt, et al. · Gut · 3
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose–volume constraints development: a study protocol
2024 · Rita Simões, Sarah Gulliford, et al. · BMJ Open · 2
PDF
Works count: 56
Citation count: 2,804
H-index: 15
I10-index: 18
Year
Topic
Type